NeuraClick announced the appointment of Dr. Gavin Dawe and Dr. Tomi Sawyer to its Scientific and Translational Advisory Board to strengthen capabilities in CNS and neuro-metabolic disorders.1
Dr. Dawe provides expertise in neuropeptide systems for modulating brain circuits and translating biology into neurotherapeutics.1
Dr. Sawyer offers strategic guidance on peptide therapeutic development, emphasizing NeuraClick's platform for improved stability, pharmacokinetics, and tissue exposure.1
These appointments support NeuraClick's advancement toward clinical development and partnerships, as stated by CEO Dr. Subhi Marwari.1
Separately, NeuraClick appointed industry veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor in September 2025 to guide pipeline growth in neuropsychiatric and metabolic disorders.23
Sources:
1. https://www.benzinga.com/pressreleases/26/04/g51828420/neuraclick-expands-scientific-and-translational-leadership-with-key-advisory-appointments
2. https://www.pharmanow.live/latest-news/neuraclick-appoints-daniel-bradbury